. Rat and guinea pig pancreatic acini possess both VIP 1 and VIP 2 receptors, which mediate enzyme secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G64-G74, 2000.-Pancreatic acini from most species possess vasoactive intestinal peptide (VIP) receptors. Recently, two subtypes of VIP receptors, VIP 1 -R and VIP 2 -R, were cloned. Which subtype exists on pancreatic acini or mediates secretion is unclear. To address this, we examined pancreatic acini from both rat and guinea pig. VIP 1 -R and VIP 2 -R mRNA were identified in dispersed acini from both species by Northern blot analysis and in rat by Southern blot analysis. With the use of the VIP 2 -R-selective ligand Ro-25-1553 in both species, inhibition of binding of 125 I-labeled VIP to acini showed a biphasic pattern with a high-affinity component (10%) and a second representing 90%. The VIP 1 -R-selective ligand, [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF-(8-27), gave a monophasic pattern. Binding of Ro-25-1553 was better fit by a two-site model. In both rat and guinea pig acini, the dose-response curve of Ro-25-1553 for stimulation of enzyme secretion was biphasic, with a high-affinity component of 10-15% of the maximal secretion and a lowaffinity component accounting for 85-90%. At low concentrations (10 nM) of Ro-25-1553 and [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF(8-27), which only occupy VIP receptors, a 4-fold and a 56-fold increase in cAMP occurred, respectively. These results show that both VIP 1 -R and VIP 2 -R subtypes exist on pancreatic acini of rat and guinea pig, their activation stimulates enzyme secretion by a cAMP-mediated mechanism, and the effects of VIP are mediated 90% by activation of VIP 1 -R and 10% by VIP 2 -R. Because VIP has a high affinity for both VIP-R subtypes, its effect on pancreatic acini is mediated by two receptor subtypes, which will need to be considered in future studies of the action of VIP in the pancreas.
vasoactive intestinal peptides; adenosine 3Ј,5Ј-cyclic monophosphate; pancreatic secretion; vasoactive intestinal peptide receptors VASOACTIVE INTESTINAL PEPTIDE (VIP) is a naturally occurring 28-amino acid peptide originally isolated from porcine duodenum that has widespread effects on many tissues, functioning primarily as a neurotransmitter (7) . Pancreatic acinar cells from most species possess VIP receptors, and activation of high-affinity VIP receptors is coupled to activation of adenylate cyclase, increased cellular cAMP, and stimulation of enzyme secretion (2, 8, 10) . Numerous studies have explained the relationship between VIP receptor occupation and changes in biological activity in acinar cells in different species (2, 7, 8, 10 ). These studies demonstrate that the exact relationship remains unclear due to the occurrence of multiple binding sites, lack of highly selective antagonists, the fact that VIP interacts with VIP and secretin receptors, both of which are present and coupled to adenylate cyclase, and that there is varying selectivity of different agonists in different species for VIP receptors over related receptors (2, 6, 18) . In guinea pig, studies of binding of 125 I-labeled VIP to pancreatic acinar cells indicate that these cells have two functionally distinct classes of receptors, each of which can interact with VIP and secretin and that highand low-affinity states of the VIP receptors exist (18, 37, 38) . In rat pancreatic acini, a different pattern occurs, in which four classes of receptors are necessary to account for the receptor interaction and the changes in biological activity caused by VIP and secretin (2, 6) .
Recently, two subtypes of VIP receptors, a VIP subtype 1 receptor (VIP 1 -R) and a VIP subtype 2 receptor (VIP 2 -R), were cloned (5, 17, 23, 32) . However, at present, it is not clear whether either or both of these VIP receptor subtypes exist on pancreatic acini. Therefore, the presence of these two subtypes on pancreatic acini could be an important factor in the relationship of the ability of VIP to occupy pancreatic acinar cell receptors and alter biological activity and could partially explain some of the complexity of binding sites previously described. Moreover, there are no functional studies or ligand-binding studies to suggest whether either or both VIP receptor subtypes are responsible for mediating the action of VIP on pancreatic acini in any species. Therefore, the purpose of the present study was to determine whether either or both VIP receptor subtypes exist in the pancreatic acini in the rat and guinea pig and to determine whether activation of the VIP 1 -R or VIP 2 -R alters cell function. Our results demonstrated for the first time that both VIP receptor subtypes exist on pancreatic acini in rat and guinea pig and that both are responsible for mediating the action of VIP on enzyme secretion in both species and are coupled to adenylate cyclase in acinar cells.
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MATERIALS AND METHODS

Materials
Male guinea pigs (100-150 g) were obtained from Charles River (Wilmington, DE). Male Sprague-Dawley rats (80-100 g) were obtained from Taconic Farm (Germantown, NY). Chinese hamster ovary (CHO) cells and Sup-T1 cells were obtained from American Type Culture Collection (Manassas, VA). CHOP cells were a gift from Dr. James W. Dennis, Samuel Lunenfeld Research Institute, Toronto, Canada (15) . Porcine vasoactive intestinal peptide (VIP) and porcine secretin were from Bachem Bioscience (King of Prussia, PA); purified collagenase (type CLSPA) was from Worthington Biochemicals (Freehold, NJ); basal medium Eagle (BME) amino mixture, BME vitamin solution, and lipofectamine transfection reagent were from Life Technologies (Gaithersburg, MD); Geneticin (G418 sulfate) was from Mediatech; pcDNA 3.1(ϩ) and pcDNA 3.1(Ϫ) were from Invitrogen (Carlsbad, CA); cAMP, bacitracin, soybean trypsin inhibitor, 1,3-dimethylxanthine (theophylline) 27 ]VIP(1-7)-GRF-(8-27) (a VIP analog selective for VIP 1 -R) (12, 14) were synthesized using standard solid phase methods as generally described previously (30) . The crude hydrogen fluoride-cleaved peptides were purified on a column (2.5 ϫ 90 cm) of Sephadex G-50, which was eluted with 1 M acetic acid. Further purification was performed by the preparative medium pressure chromatography on a column (1.5 ϫ 45 cm) of Vydac C18 silica (10-15 mm), which was eluted with linear gradients of acetonitrile in 0.1% (vol/vol) trifluoroacetic acid (flow rate of 6 ml/min). Peptides were purified further by rechromatography on the same column with slight modifications of gradient conditions. Homogeneity of the peptides was assessed by TLC and analytical reverse-phase HPLC, and purity was at least 97% for each peptide. Amino acid analysis gave the expected amino acid ratios. Each analog gave good recovery of the molecular ion corresponding to the calculated molecular mass.
Preparation of dispersed pancreatic acini. Dispersed acini from guinea pig and rat were prepared using the modification (20) of the method described previously (27) . Unless specified otherwise, dispersed acini from the pancreas of one animal were suspended in 100 ml of standard incubation solution. All incubations were at 37°C. The incubation solution was equilibrated with 100% O 2 , and incubations for measurement of amylase release and cAMP release were performed with 100% O 2 as the gas phase.
Northern blot analysis. Total RNA was extracted from rat (r) VIP 1 -R and rVIP 2 -R stably transfected CHO cells, rat jejunum, rat whole pancreas, rat pancreatic acini, and guinea pig pancreas and guinea pig pancreatic acini that had been snap frozen in liquid nitrogen followed by pulverization in liquid nitrogen using the RNeasy Midi kit (Qiagen, Chatsworth, CA). Approximately 15 µg of total RNA samples from each tissue were subjected to denaturing gel electrophoresis in formaldehyde agarose [0.22 M and 1% (wt/vol), respectively] and then transferred to a nitrocellulose membrane (Schleicher & Schuell, Keene, NH) according to the methods of Thomas (33) . The probe for the rVIP 1 -R (a 316-bp fragment) was generated from the rat jejunum. The gene-specific PCR primers used were as follows: 5Ј-CTGGCAGGAGCCCTT-GCCTG-3Ј (sense) and 5Ј-GTTGCTGCTCATCCAGACTCG-3Ј (antisense). The probe for rVIP 2 -R (a 326 bp fragment) was generated from the rat antrum. The gene-specific PCR primers used were as follows: 5Ј-TCCACCCAGAATGCCG-GTTTC-3Ј (sense) and 5Ј-GTGATCTTACTCTCATCCTCGG-3Ј (antisense). DNA sequence of the PCR products was verified by automatic sequencing on both strands. The fragments were cloned in the expression vector pCR2.1 using TA cloning kit (Invitrogen, San Diego, CA). The PCR reaction was carried out with GeneAmp PCR system (Perkin-Elmer, Foster City, CA) using the following conditions: an initial step of 3 min at 95°C; 35 cycles of 30-s denaturation at 95°C, 30-s annealing at 45°C, and 1-min extension at 75°C with a 5-min final extension at 75°C. Hybridization was carried out at 37°C using probes labeled with the random primer DNA labeling system (Life Technologies) in a buffer containing 40% (vol/vol) formamide (Fluka Chemical), 4ϫ SCC (300 mM NaCl and 30 mM sodium citrate; Research Genetics, Huntsville, AL), 20 mM Tris, pH 7.5 (Quality Biological, Gaithersburg, MD), 10% (vol/vol) dextran sulfate (Oncor, Gaithersburg, MD), 1ϫ Denhardt's solution (Digene Diagnostics, Beltsville, MD), and 20 µg/ml sonicated herring sperm DNA (Digene Diagnostics, Beltsville, MD). Nitrocellulose filters of Northern blot transfers were hybridized overnight with the rVIP 1 -R and rVIP 2 -R cDNA, respectively, after radiolabeling to a specific activity of about 1 ϫ 10 9 cpm/µg DNA. Filters were washed sequentially, with increasing stringency, ending with a final wash in 0.1ϫ SSC-0.1% SDS (vol/vol) at 55°C, air-dried, and exposed to X-ray films (XAR, Eastman Kodak).
Southern blot analysis. Total RNA from rat whole pancreas, dispersed rat pancreatic acini, and rat jejunum was used to synthesize first-strand cDNA. The first-strand cDNA was synthesized using 1.0 µg of total RNA with a first-strand cDNA synthesis kit using random hexamer primers (Life Technologies). For amplification from the first-strand cDNAs, the same gene-specific primers for rVIP 1 -R and rVIP 2 -R performed for Northern blot were used as described above. The PCR reaction was performed under the following conditions: an initial step of 3 min at 95°C, 35 cycles of 30-s denaturation at 95°C, 30-s annealing at 45°C, and 1-min extension at 75°C with a 5-min final extension at 75°C. The PCR products were electrophoretically separated in 1.2% (wt/vol) SeaKem GTG agarose gels (FMC BioProducts, Rockland, ME) and transferred to nitrocellulose. Nitrocellulose filters of Southern blot transfers were hybridized at room temperature with the 32 P-end-labeled rVIP 1 -R probe (316-bp fragment) and rVIP 2 -R probe (326-bp fragment) as described under Northern blot analysis. The filters were then washed at room temperature, air-dried, and exposed to X-ray film for several hours.
Cell culture. The rVIP 1 -R/CHOP and rVIP 2 -R/CHOP (i.e., rat VIP 1 -R or rat VIP 2 -R transiently transfected into CHOP cells) were grown in DMEM supplemented with 10% (vol/vol) fetal bovine serum, 1% (vol/vol) antibiotics, and 200 µg/ml G418. The rVIP 1 -R/CHO, rVIP 2 -R/CHO, hVIP 1 -R/CHO, and hVIP 2 -R/CHO (i.e., rat or human VIP 1 -R and rat or human VIP 2 -R stably expressed in CHO cells) were grown in Ham's medium supplemented with 10% (vol/vol) fetal bovine serum, 1% (vol/vol) antibiotics, and 300 µg/ml G418. Cultures were maintained in incubators at 37°C in an atmosphere of 5% CO 2 and 95% air.
Construction of rVIP 1 -R cDNA, rVIP 2 -R cDNA, hVIP 1 -R cDNA, and hVIP 2 -R cDNA. Total RNA was extracted from rat jejunum (contains VIP 1 -R) and rat antrum (contains VIP 2 -R), and after cDNA synthesis rVIP 1 -R and rVIP 2 -R cDNA were obtained using receptor-specific primers and RT-PCR. The full-length correct sequence was confirmed by automated sequencing on both strands using a A377 DNA sequencer (Perkin-Elmer). Both rVIP 1 -R and rVIP 2 -R cDNA were ligated into the Xba I/Hind III sites of pcDNA3.1(Ϫ) vector. hVIP 1 -R cDNA (hVIP 1 -R) was a gift from Dr. Charles D. Ulrich II, Division of Digestive Diseases, University of Cincinnati Medical Center. hVIP 1 -R cDNA was ligated into the Hind III/Xba I sites of pcDNA3.1(ϩ) vector. hVIP 2 -R cDNA was cloned from human lymphoblast Sup-T1 cells as described previously (32) and ligated into the Hind III/Xba I sites of pcDNA3.1(ϩ) vector. The full-length correct sequence of hVIP 1 -R and hVIP 2 -R were confirmed by automated sequencing on both strands using a A377 DNA sequencer.
Transient transfection of CHOP cells with rVIP 1 -R and rVIP 2 -R. CHOP cells were maintained in DMEM supplemented with 10% (vol/vol) fetal bovine serum, 1% (vol/vol) antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin), and 200 µg/ml G418 sulfate. Subconfluent CHOP cells were grown in 100-mm-diameter culture plates and transfected with 5 µg plasmid DNA rVIP 1 -R and rVIP 2 -R, respectively, in the expression vector pcDNA3.1(Ϫ) using the lipofectamine transfection reagent. Transfected cells were grown for 2 days and used for binding studies.
Transfection of CHO cells with rVIP 1 -R, rVIP 2 -R, hVIP 1 -R, and hVIP 2 -R and selection of stable transfectants. CHO-K1 cells were maintained in Ham's medium supplemented with 10% (vol/vol) fetal bovine serum and 1% (vol/vol) antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin). Subconfluent CHO cells were grown in 100-mm-diameter culture plates and transfected with 5 µg of plasmid DNA rVIP 1 -R and rVIP 2 -R, respectively, in the expression vector pcDNA3.1(Ϫ) and plasmid DNA hVIP 1 -R and hVIP 2 -R, respectively, in the expression vector pcDNA3.1(ϩ), using the lipofectamine transfection reagent according to the manufacturer's instructions. Transfected cells were grown for 2 wk in medium containing 800 µg/ml G418 sulfate. Individual colonies were isolated and expanded, and cloned cells were screened for each VIP-R subtype expression by receptor binding of 125 I-labeled VIP.
Binding studies. Binding of 125 I-VIP to pancreatic acini was performed as described previously (8, 21, 38) . Briefly, dispersed acini from the pancreas of two guinea pigs or two rats were suspended in 15-20 ml of standard incubation solution containing 0.05% (wt/vol) bacitracin. 125 I-VIP was added at 50 pM without (total binding) or with 1 µM VIP (nonsaturable binding). Acini were incubated for 45 min at 37°C. Samples (100 µl) of cell suspension were centrifuged through silicon oil (d ϭ 1.05) in Microfuge tubes to separate bound from unbound ligand. The tubes were washed twice with 4% (wt/vol) BSA in standard incubation solution, and radioactivity was determined by a Packard Auto-Gamma counter (Meriden, CT). Nonsaturable binding for 125 I-VIP was Ͻ3% of total binding.
Binding of 125 I-VIP to rVIP 1 -R/CHOP, rVIP 2 -R/CHOP, rVIP 1 -R/CHO, rVIP 2 -R/CHO, hVIP 1 -R/CHO, and hVIP 2 -R/CHO cells was performed by incubation in standard incubation solution containing 0.05% (wt/vol) bacitracin for 60 min at room temperature. The separation of bound from free radioactivity was obtained by centrifugation of cells through 2% (wt/vol) BSA in standard incubation solution. The tubes were washed twice with 2% (wt/vol) BSA in standard incubation solution, and radioactivity was counted. Nonsaturable binding for 125 I-VIP was Ͻ5% of total binding.
For all peptides, the IC 50 was calculated, which was the concentration that gave half-maximal inhibition of that seen with a maximally effective concentration of VIP (1 µM). The IC 50 was calculated using the curve-fitting program Kaleidograph, and the affinity constant and binding capacity were determined using the least-squares, curve-fitting program LIGAND (24) .
Assessment of amylase release from pancreatic acini. Amylase release was measured using the procedure published previously (20, 27) . Briefly, dispersed acini from one rat pancreas were suspended in standard incubation solution, whereas dispersed acini from one guinea pig pancreas were suspended in standard incubation solution containing 5 mM theophylline. Incubations contained 0.5 ml of cell suspension and were at 37°C for 30 min. Amylase activity was determined using the Phadebas reagent and was expressed as the percentages of the cellular amylase released into the extracellular medium during the incubation.
For all peptides, the EC 50 was calculated, which was the concentration of the peptide that gave half-maximal stimulation of a maximally effective concentration of VIP (10 nM). The EC 50 was calculated using the curve-fitting program Kaleidograph.
cAMP release from guinea pig pancreatic acini. Cellular cAMP was determined by RIA as described previously (2, 37, 38) . Guinea pig pancreatic acinar cells were suspended in 50-2,000 ml of standard incubation solution containing 1 mM IBMX. Incubations contained 0.5 ml of cell suspension and were at 37°C for 30 min. The concentration of pancreatic acinar cells was adjusted to maintain cAMP on the linear portion of the standard curve. Results were expressed as the value obtained with the indicated peptide (experiment) over the value obtained with no peptide added (control).
Statistical Analysis
The results are means Ϯ SE of three or more experiments. The statistical comparisons were performed using ANOVA with the Dunnett's test, and a P value of Ͻ0.05 was considered significant. EC 50 were calculated using the curve-fitting program Kaleidograph. Binding curves were fitted using the least-squares curve fitting program LIGAND (24) to calculate dissociation constant (K d ) values.
RESULTS
Expression of Subtypes of VIP Receptors in the Pancreas in the Rat and Guinea Pig
To determine whether both subtypes of VIP receptors existed in the pancreas in the rat and guinea pig, Northern blot analysis was used initially (Fig. 1) . CHO-K1 cells stably transfected with rVIP 1 -R and rVIP 2 -R were included as a positive control as well as rat jejunum, because jejunum is reported to express moderately both VIP 1 -R and VIP 2 -R (34). The VIP 1 -R and VIP 2 -R probes specifically interacted only with the VIP 1 -R mRNA and VIP 2 -R mRNA, respectively, under the conditions used (Fig. 1A) . VIP 1 -R mRNA and VIP 2 -R mRNA were identified in jejunum as well as in both whole pancreas and dispersed pancreatic acinar cells from both species (Fig. 1) . Similarly, with the use of Southern blot analysis (Fig. 2) , both VIP 1 -R and VIP 2 -R were detectable in both whole pancreas and dispersed pancreatic acinar cells from rat. These results indicated that pancreatic acini of both rat and guinea pig express both VIP 1 -R and VIP 2 -R subtypes.
Determination of the Presence and Function of the Two VIP Receptor Subtypes
To determine whether both VIP receptor subtypes were present and the effect of their cellular activation on cell function in acini, selective ligands for the VIP 1 -R and VIP 2 -R receptors were needed. [Lys 15 ,Arg 16 ,Leu 27 ] VIP-(1-7)-GRF-(8-27) is reported to be a selective VIP 1 -R ligand functioning as an agonist of rVIP 1 -R and hVIP 1 -R (12). Ro-25-1553 is reported to have selectivity for the VIP 2 -R, functioning as an agonist of rVIP 2 -R (35) Fig. 2 . Autoradiograph of Southern blot after RT-PCR using gene-specific primers for rVIP 1 -R and rVIP 2 -R. Reverse transcription was performed using total cellular RNA. PCR was performed with gene-specific primers for rVIP 1 -R and rVIP 2 -R as described under Methods. Hybridization was performed using 32 Pradiolabeled gene-specific probes as described under Methods. A: results with a rVIP 1 -Rspecific probe. B: results with a rVIP 2 -Rspecific probe. Fig. 1 . Northern blot analysis to detect expression of rat vasoactive intestinal peptide receptors (rVIP 1 -R and rVIP 2 -R) or guinea pig (gp) tissue mRNA in transfected Chinese hamster ovary (CHO) cells, jejunum, pancreas, and dispersed pancreatic acini. Fifteen micrograms of total cellular RNA isolated from each tissue and from pancreatic acinar cells from rat and guinea pig were analyzed by Northern blot, and subsequent gene-specific hybridization was performed as described under Methods. A: autoradiograms of mRNA from rVIP 1 -R-and rVIP 2 -R-transfected CHO-K1 cells. B: autoradiograms of mRNA from rat tissues. C: autoradiograms of mRNA from guinea pig tissues analyzed using a specific rVIP 1 -R or rVIP 2 -R probe. Rat jejunum contains both VIP 1 -R and VIP 2 -R and was used as a control. Bottom panels show positions of the 28S and 18S ribosomal RNAs. and hVIP 2 -R (13). To determine the selectivity of these two ligands, their affinities for rVIP 1 -R or rVIP 2 -R transiently expressed in CHOP cells and CHO cells stably expressing rVIP 1 -R, rVIP 2 -R, hVIP 1 -R, or hVIP 2 -R were determined (Table 1, Fig 3) . As described previously (1, 11, 12, 22, 31, 34) , VIP was found to interact with similar high affinity (IC 50 of 0.53 Ϯ 0.01) with CHO cells stably expressing rVIP 1 -R (Fig. 3A) or rVIP 2 -R (Fig. 3B) . With both rVIP receptors stably expressed in CHO-K1 cells, the VIP dose-inhibition curve was broad, spanning at least four log units (Fig. 3) . Computer analysis (LIGAND) of the VIP dose-inhibition curve (n ϭ 3) for 125 I-VIP binding demonstrated with the rVIP 1 -R (P ϭ 0.006) and the rVIP 2 (n ϭ 3) (P Ͻ 0.001) CHO-K1 cells that both were fitted significantly better by a two-binding site than a single-binding site model. (Table 1) . In CHO cells stably transfected with either rVIP 1 -R or rVIP 2 -R, each of the three peptides inhibited binding of 125 I-VIP; however, they differed in affinity for the two receptors (Fig. 3, Table 1 ). In CHO cells stably transfected with rVIP 1 -R or rVIP 2 -R, whereas VIP had similar affinity for both rVIP receptors, [Lys 15 ,Arg 16 ,Leu 27 ] VIP(1-7)-GRF(8-27) had a Ͼ169-fold higher affinity for rVIP 1 -R and Ro-25-1553 had a 241-fold higher affinity for rVIP 2 -R (Fig. 3, Table 1 ). Similarly, in CHO cells stably transfected with hVIP 1 -R or hVIP 2 -R, VIP had a 6.4-fold higher affinity for hVIP 1 -R, whereas [Lys 15 ,Arg 16 ,Leu 27 ] VIP-(1-7)-GRF(8-27) had a Ͼ1,765-fold higher affinity for hVIP 1 -R and the Ro-25-1553 had a 280-fold higher affinity for hVIP 2 -R (Fig. 3 , Table 1 ).
In guinea pig pancreatic acini, inhibition of binding of 125 I-VIP by VIP showed a broad dose-inhibition curve with detectable inhibition at 0.03 nM, half-maximal inhibition at 1.8 nM, and complete inhibition at 1 µM (Fig. 4A) . The VIP 1 -R-selective ligand [Lys 15 ,Arg 16 ,Leu 27 ] VIP-(1-7)-GRF-(8-27) showed a similar dose-inhibi- Values are means Ϯ SE. Data are calculated from experiments shown in Fig. 3 . IC 50 was the concentration of peptide that caused a half-maximal inhibition of the value that was seen with 1 µM VIP calculated from the dose-inhibition curve using Kaleidograph. rVIP-R and hVIP-R, rat and human vasoactive intestinal peptide receptors, respectively; CHO, Chinese hamster ovary. tion curve to VIP but was 2.3-fold less potent, causing a half-maximal inhibition at 4.1 nM, which was significantly less (P Ͻ 0.01) than the potency of VIP (Table 2 ) . In contrast, the VIP 2 -R-selective ligand Ro-25-1553 showed a biphasic pattern of inhibition with an initial plateau representing 10% of the total binding from 1 to 10 nM (Fig. 4A) . A second component of inhibition occurred at concentrations of Ro-25-1553 Ͼ10 nM, representing 90% of the total binding (Fig. 4A) . Ro-25-1553 caused half-maximal inhibition of the highaffinity component at 0.43 Ϯ 0.001 nM and halfmaximal inhibition of the low-affinity component at 1.7 Ϯ 0.1 µM (Fig. 4A; Table 2 ). A similar result was seen in rat pancreatic acini (Fig. 4B) . Specifically, inhibition of binding of 125 I-VIP by VIP in rat acini also showed a broad dose-inhibition curve with detectable inhibition at 0.03 nM, half-maximal inhibition at 1.7 nM, and complete inhibition at 1 µM (Fig. 4B) . The VIP 1 -R-selective ligand [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF-(8-27) showed a similar dose-inhibition curve to VIP but was 15.8-fold less potent, causing a halfmaximal inhibition at 26.9 nM. Similar to guinea pig acini, the dose-inhibition curve of Ro-25-1553 in rat acini was biphasic, with 10% of the total binding to a receptor with high affinity for Ro-25-1553 and 90% to a site with low affinity for Ro-25-1553 (Fig. 4B) . Ro-25-1553 caused half-maximal inhibition of the highaffinity component at 0.21 Ϯ 0.001 nM and halfmaximal inhibition of low-affinity component at 457 Ϯ 13 nM (Fig. 4B, Table 2 ). Therefore, although VIP and Ro-25-1553 had similar affinities for VIP receptors on rat and guinea pig pancreatic acini, [Lys 15 ,Arg 16 ,Leu 27 ] VIP-(8-27) had a fivefold lower affinity for rat than guinea pig pancreatic acini (Table 2 ). To confirm further the presence of two distinct binding sites, the 125 I-VIP dose-inhibition curves of VIP and Ro-25-1553 were analyzed using the least-squares curve-fitting program LIGAND (24) . In guinea pig pancreatic acini, as reported previously (18, 38) Values are means Ϯ SE from at least 3 separate experiments. In each experiment, each value was determined in duplicate. Dose-response curve for Ro-25-1553 was biphasic for both amylase release (Figs. 5 and 6) and inhibiting of binding of 125 I-VIP (Figs. 3 and 4) . Concentration of Ro-25-1553 causing half-maximal stimulation (EC 50 ) of the first phase of amylase release was that concentration causing half-maximal stimulation of the value caused by 0.3 nM Ro-25-1553. For the second phase, EC 50 was calculated as concentration of peptide that caused a half-maximal stimulation of the increase seen with 10 nM VIP. Concentration of Ro-25-1553 causing half-maximal inhibition (IC 50 ) of the first phase of 125 I-VIP binding was that concentration causing half-maximal inhibition of the value caused by 1 nM Ro-25-1553. For the second phase, IC 50 was calculated as concentration of peptide that caused a half-maximal inhibition of the value that was seen at 1 µM VIP. To determine whether either or both VIP receptor subtypes mediate enzyme secretion, the ability of each selective agonist to cause amylase release from both species was examined. In guinea pig pancreatic acini, amylase release by VIP showed a broad dose-response curve with a detectable increase at 1 pM, half-maximal stimulation of increase at 0.05 nM, and maximal stimulation at 10 nM (Fig. 5A, Table 2 ). The VIP 1 -R-selective ligand [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF-(8-27) showed a similar dose-response curve for increasing amylase to VIP but was 34-fold less potent, causing a half-maximal stimulation at 1.7 Ϯ 0.04 nM (Fig. 5A, Table 2 ). In contrast, Ro-25-1553 had a biphasic dose-response curve with a high-affinity component accounting for 15% of the maximal secretion seen between 0.01 and 1 nM (EC 50 of 0.0025 Ϯ 0.0009 nM) and a second low-affinity component accounting for 85% of the maximal secretion seen at concentrations of 1 µM (EC 50 of 20.4 Ϯ 0.9 nM) (Fig. 5A , Table 2 ). Similarly, in rat pancreatic acini, amylase release by VIP showed a broad dose-response curve with a detectable increase at 3 pM, half-maximal stimulation of increase at 0.09 nM, and maximal stimulation at 10 nM (Fig.  5B , Table 2 ). The VIP 1 -R-selective ligand [Lys 15 ,Arg 16 , Leu 27 ]VIP-(1-7)-GRF- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) showed a similar dose response to VIP but was 96.7-fold less potent, causing a half-maximal stimulation at 8.7 Ϯ 0.34 nM (Fig. 5B, Table  2 ). Similar to guinea pig acini, Ro-25-1553 had a biphasic dose-response curve with a high-affinity component accounting for 10% of the maximal secretion seen between 0.01 and 1 nM (EC 50 of 0.0045 Ϯ 0.0003 nM) and a second component accounting for 90% of the maximal secretion seen at concentrations of 1 µM (EC 50 of 52.4 Ϯ 4.9 nM) (Fig.  5, Table 2 ). These results indicated that activation of both subtypes can stimulate enzyme secretion; however, activation of the VIP 1 -R is principally responsible for enzyme secretion because its activation caused 85% and 90% of the maximal secretion, whereas VIP 2 -R only caused 10% and 15% of maximal secretion in the guinea pig and the rat, respectively.
Previous studies have demonstrated that VIP causes increases in cAMP in rat and guinea pig pancreatic acini, and this increase stimulates enzyme secretion (2, 3, 18, 28, 37, 38) . To investigate whether activation of both VIP 1 -R and VIP 2 -R can cause activation of adenylate cyclase and increased cAMP, we examined the ability of each selective agonist to alter cAMP levels in guinea pig pancreatic acini. Rat and guinea pig pancreatic acini possess both VIP and secretin receptors, which are both coupled to adenylate cyclase, and can both be activated by high concentrations of VIP (2, 3, 18, 29, 37, 38) ; therefore, it is important to test low concentrations of VIP agonist, which only activate VIP receptors. VIP at the dose of 1 nM, which only activates VIP receptors, caused a 54.2 Ϯ 5.7-fold increase in cAMP (Table 3 ). The VIP 1 -Rselective agonist [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) at the dose of 10 nM, which only occupies VIP 1 -R, increased cAMP release by 56.3 Ϯ 3.9-fold (Table 3) , Values are means Ϯ SE from at least 3 separate experiments. In each experiment, each value was determined in triplicate. Acini were suspended in standard incubation solution with 1 mM IBMX and incubated for 30 min at 37°C with agents specified. Results for cAMP were calculated as the value with a particular agent (experimental) divided by the value measured at the same time in incubations containing no additions (control). Control value was 95.2 Ϯ 17.9 pm of cAMP/mg protein, and the maximal value seen with 1 µM secretin was 10,091 Ϯ 1998 pm of cAMP/mg protein (n ϭ 3). ND, not done.
demonstrating that VIP and [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) have equal efficacy at low concentrations. The VIP 2 -R-selective agonist Ro-25-1553 at the dose of 10 nM, which only occupies VIP 2 -R, caused a 3.7 Ϯ 0.3-fold increase in cAMP, which was 15.2-fold lower than that seen with VIP 1 -R activation by the VIP 1 -R-selective ligand [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (Table 3 ). At high concentrations (i.e., Ն1 µM) in guinea pig acini, VIP-related peptides can stimulate cAMP through both VIP receptors and secretin receptors, which are both coupled to adenylate cyclase (10, 18, 19, 28, 37, 38) . VIP, secretin, and the VIP-related peptides, [Lys 15 ,Arg 16 ,Leu 27 ]-VIP(1-7)-GRF-(8-27) and Ro-25-1553, all stimulated Ͼ85-fold increase in cAMP at 1 µM concentrations, demonstrating activation of both the VIP and secretin receptor (Table 3) .
DISCUSSION
High-affinity receptors for VIP have been shown by binding studies or functional assays measuring changes in cellular function in pancreatic acinar cells from a number of species, including mouse, rat, and guinea pig (18) . In each of these species, activation of high-affinity VIP receptors either stimulated enzyme secretion itself or potentiated stimulated enzyme secretion by other secretagogues such as CCK or muscarinic cholinergic agents (4, 9, 18) . Similar to secretin receptors, which also occur in pancreatic acinar cells of each of these species (2, 6, 18, 19) , activation of high-affinity VIP receptors is coupled to activation of adenylate cyclase and increases in cellular cAMP. The exact relationships between receptor occupation, adenylate cyclase activation, and enzyme secretion in different species are complicated by the occurrence of multiple binding sites, lack of antagonists with high selectivity, and varying selectivity for different agonists in different species (2, 6, 18) . For example, in rat pancreatic acini, it has been proposed that VIP and secretin interact with four classes of receptors (2, 6), of which VIP interacts with two classes in one study (2) and in another study with one class (6) . In guinea pig pancreatic acini, VIP at a high concentration interacts with both the VIP and secretin receptors; moreover, the VIP receptor can exist in both low-and high-affinity states (18, 37, 38) . All of these studies were performed before it was discovered that two distinct subtypes of VIP receptors exist: a 459-amino acid VIP 1 -R in the rat (rVIP 1 -R) (17) and a 437-amino acid VIP 2 -R in the rat (rVIP 2 -R) (23) , which have 50% amino acid homology. VIP 1 -R and VIP 2 -R have been cloned from rat (17, 23) and human (5, 32) tissues. Both receptor subtypes are coupled to G s ␣ proteins, and their occupancy by agonists stimulates adenylate cyclase activity. VIP has a high affinity for both rat and human VIP 1 -R and VIP 2 -R, whereas secretin has a low affinity for both rat and human VIP 1 -R and VIP 2 -R (11, 12) . Whether either or both of these VIP receptor subtypes exist on pancreatic acini was unclear, until the present study.
In previous studies using Northern blot analysis, VIP 1 -R mRNA was not detected in the rat pancreas (17) and VIP 2 -R mRNA was detected only in the rat pancreatic islets (16) . In another study, Usdin et al. (34) did not detect either VIP 1 -R or VIP 2 -R in the rat pancreas by Northern blot analysis, whereas they detected both VIP 1 -R and VIP 2 -R in the rat pancreas by Southern blot analysis after RT-PCR. However, with the use of in situ hybridization, they showed that VIP 1 -R mRNA is only clearly observed in blood vessels within the pancreas and VIP 2 -R in islets throughout the pancreas (34) . With respect to normal rat pancreas, their data suggest that rVIP 1 -R is expressed exclusively in the walls of blood vessels, whereas rVIP 2 -R is only in pancreatic islets (16, 17, 34) . In normal human pancreas, VIP 2 -R mRNA was detected by Northern blot analysis (1) and by RNase blot analysis (36) , whereas VIP 1 -R mRNA was not detected by Northern blot analysis (31) . However, by Southern blot hybridization after RT-PCR, both VIP 1 -R and VIP 2 -R were reported to be identified in the human pancreas (22, 36) . Before the present study, there were no functional studies or ligand binding studies to suggest whether either or both VIP receptor subtypes exist on pancreatic acini in any species.
A number of the results from the Northern and Southern blot analysis performed in the present study support the conclusion, combined with the functional studies of amylase release, that in both rat and guinea pig pancreatic acinar cells both VIP 1 -R and VIP 2 -R are present. First, by Northern blot analysis, both VIP 1 -R and VIP 2 -R mRNA were found in rat and guinea pig pancreas. Second, in rat pancreas with PCR with Southern blot analysis, both rVIP 1 -R and rVIP 2 -R were detected. Third, to further ascertain whether the receptors were on pancreatic acinar cells, a similar analysis was performed on dispersed acini from rat and guinea pig pancreas. In dispersed pancreatic acini from both species, both VIP 1 -R and VIP 2 -R were present. These results were not due to cross-hybridization because both probes were shown to be specific for either the VIP 1 -R or the VIP 2 -R in both the Northern and Southern blot analysis in a control tissue. Because isolated pancreatic acinar preparations can be contaminated by small numbers of pancreatic islets or centroacinar cells, the Northern and Southern blot results alone do not establish that the VIP receptors are in acinar cells. However, the ability of selective agonists for these two VIP-R receptor subtypes to stimulate enzyme secretion, discussed below, establish that these receptors are on pancreatic acinar cells.
To demonstrate the presence of both receptor subtypes directly by binding studies and to perform studies of the ability of either VIP receptor subtype to alter pancreatic acinar cell function, we needed to identify selective ligands for each VIP receptor subtype.
[Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) ) is reported to be a selective agonist for VIP 1 -R (12) and Ro-25-1553 is reported to have selectivity to VIP 2 -R (13, 35) . We confirmed the selectivity of these two ligands by examining their affinities for rat and human VIP 1 -R and VIP 2 -R expressed in CHOP cells by transient expression and CHO cells stably expressing rVIP 1 -R, rVIP 2 -R, hVIP 1 -R, or hVIP 2 -R. [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF-(8-27) showed a 53-fold and over a 169-fold selectivity for the rVIP 1 -R in CHOP cells and CHO cells, respectively, and showed over a 1,765-fold selectivity for the hVIP 1 -R in CHO cells. Ro-25-1553 showed over a 4,412-fold and a 241-fold selectivity for the rVIP 2 -R in CHOP cells and CHO cells, respectively, and showed a 280-fold selectivity for the hVIP 2 -R in CHO cells. These results suggested that these two agonists could be useful tools for distinguishing between VIP 1 -R and VIP 2 -R in binding studies and studies of biological activity.
A number of results from the binding studies support the conclusion that both rat and guinea pig pancreatic acini possess both the VIP 1 -R and the VIP 2 -R, with the VIP 1 -R the predominant subtype. First, the doseinhibition curve of the VIP 2 -R-selective ligand Ro-25-1553 showed a biphasic pattern of inhibition, with a high-affinity component representing 10% of the total saturable 125 I-VIP binding and a second component representing 90% of the total saturable 125 I-VIP binding in both species. These results demonstrated that 10% of the radioligand 125 I-VIP is bound to receptors with high affinity for the VIP 2 -R-selective ligand and that 90% of the saturable binding of 125 I-VIP is to receptors with low affinity for the VIP 2 -R-selective ligand. Second, the VIP 1 -R-selective ligand [Lys 15 ,Arg 16 ,Leu 27 ] VIP-(1-7)-GRF-(8-27) gave a monophasic dose-inhibition curve of 125 I-VIP binding, which was parallel to the VIP dose-inhibition curve compatible with the conclusion that 125 I-VIP was primarily bound to receptor sites with high affinity for the VIP 1 -R ligand. Third, we verified that 125 I-VIP was both binding to a site with high affinity for the VIP 1 -R and the VIP 2 -R by analyzing the 125 I-VIP dose-inhibition curve of the VIP 2 -Rselective agonist Ro-25-1553 using a least-squares, curve-fitting program (24) . The analysis in the guinea pig pancreatic acini demonstrated that the doseinhibition curve of Ro-25-1553 was significantly better fit by a two binding site model than a one binding site model. Furthermore, one site had a high affinity (K d ϭ 0.36 nM) for Ro-25-1553 and the other site had a low affinity (K d ϭ 2.94 µM) for Ro-25-1553. The binding sites with low affinity for Ro-25-1553 (i.e., the VIP 1 -R) were present in 19.9-fold higher numbers than those with high affinity for Ro-25-1553 (i.e., VIP 2 -R).
It is known that agonist activation of VIP receptors in rat and guinea pig pancreas results in enzyme secretion (2, 10, 18) . To determine whether activation of VIP 1 -R, VIP 2 -R, or both are coupled to enzyme secretion, we analyzed the ability of the selective VIP 1 -R and VIP 2 -R agonist ligands to stimulate enzyme secretion. In the present study, a number of results support the conclusion that activation of both VIP 1 -R and the VIP 2 -R stimulates enzyme secretion in both rat and guinea pig pancreatic acini, with the VIP 1 -R responsible for the majority of the enzyme secretion mediated by VIP receptor activation. First, the VIP 2 -R-selective ligand Ro-25-1553 showed a biphasic dose-response curve with a high-affinity component accounting for 10-15% of the maximal secretion caused by VIP and a low-affinity component accounting for 85-90% of the maximal secretion caused by VIP in both species. The VIP 2 -R-selective ligand Ro-25-1553 caused 10-15% maximal stimulation of that caused by VIP over the same concentration rate causing a 10-15% decrease in binding of 125 I-VIP, supporting the conclusion that the stimulation was due to VIP 2 receptor activation. Furthermore, this stimulation occurred over a concentration range (i.e., Ͻ10 nM) at which Ro-25-1553 only occupies VIP 2 -R. These results demonstrated that 10-15% of the maximal amylase secretion caused by VIP is through the activation of receptors with high affinity for the VIP 2 -R-selective ligand and that 85-90% of the maximal amylase secretion is through receptors with low affinity for the VIP 2 -R-selective ligand. Second, the VIP 1 -R-selective ligand [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF-(8-27) gave a monophasic dose-stimulation curve of amylase secretion that was parallel to the VIP dose-response curve, which is compatible with the conclusion that amylase secretion was primarily mediated through receptor sites with high affinity for the VIP 1 -R ligand. Third, at high concentrations at which the VIP 1 -R-selective ligand [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) ) and the VIP 2 -R-selective ligand Ro-25-1553 interact with both the VIP 1 -R and the VIP 2 -R, the efficacy of each selective analog was equal to that seen with VIP, supporting the conclusion that VIP was causing enzyme secretion by activation of both the VIP 1 -R and the VIP 2 -R.
In other cell systems, activation of either VIP 1 -R (17, 31) or the VIP 2 -R (1, 16, 23, 32) results in stimulation of adenylate cyclase and increases in cellular cAMP. In previous studies, activation of the VIP receptors in both guinea pig (10, 18, 28, 37, 38) and rat pancreatic acini (2, 6, 18) has been shown to increase cAMP, which results in enzyme secretion. A number of our results support the conclusion that activation of both VIP 1 -R and VIP 2 -R in the guinea pig pancreatic acini is coupled to increases in cAMP. First, in older studies (10, 18, 38) it was demonstrated that in guinea pig pancreas the VIP-stimulated cAMP dose-response curve is biphasic. One component is seen with VIP at low concentrations, due to VIP receptor occupation (Յ10 nM), and a second component occurs at higher concentrations, corresponding to concentrations that result in occupation of secretin receptor. In the present study, therefore, it was important to investigate increases in cAMP at low concentrations (Յ10 nM) of VIP agonists that only activate VIP receptors to assess only the result of VIP receptor activation or adenylate cyclase activity. At low concentrations (10 nM) of the VIP 2 -R-selective agonist Ro-25-1553, which would only occupy VIP 2 -R, a fourfold increase in cAMP was seen. These results demonstrate that occupation of the VIP 2 -R is coupled to adenylate cyclase and causes a fourfold increase in cAMP. Second, with a low concentration (10 nM) of the VIP 1 -Rselective agonist [Lys 15 ,Arg 16 ,Leu 27 ]VIP-(1-7)-GRF- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , which would only occupy VIP 1 -R, a 56-fold increase in cAMP was seen. This result demonstrates that occupation of the VIP 1 -R on guinea pig pancreatic acini is also coupled to adenylate cyclase and causes a 56-fold increase in cAMP. Third, VIP at 1 nM, a concentration known to activate only VIP receptors in guinea pig pancreatic acini (9, 10, 37) , caused a similar increase in cAMP to that seen with the 10 nM VIP 1 -R agonist. These results show that Ͻ10% of the cAMP caused by 1 nM VIP is due to VIP 2 -R activation and the majority (Ͼ90%) is due to VIP 1 -R activation. Fourth, at high concentrations (i.e., Ն1 µM), VIP, secretin, and the VIP receptor subtype-selective agonists [Lys 15 ,Arg 16 ,Leu 27 ] VIP-(1-7)-GRF- (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) and Ro-25-1553 all stimulated increases in cAMP to the same degree (i.e., Ͼ85-fold). These high-agonist concentrations were causing increases in cAMP through stimulation of both the VIP and secretin receptors (3, 9, 18, 19, 37, 38) .
In conclusion, we have identified that both rat and guinea pig pancreatic acini possess both VIP 1 receptors and VIP 2 receptors, with the VIP 1 receptor the predominant subtype. Activation of both the VIP 1 -R and the VIP 2 -R stimulates enzymes in both rat and guinea pig pancreatic acini, with the VIP 1 -R responsible for the majority (i.e., Ͼ85%) of the enzyme secretion mediated by VIP receptor activation. Finally, both the VIP 1 -R and the VIP 2 -R are coupled to increases in cAMP, with Ͻ10% of the cAMP caused by a low concentration of VIP (1 nM) due to VIP 2 -R activation and the majority (Ͼ90%) due to VIP 1 -R activation. These results show for the first time that both VIP receptor subtypes exist on pancreatic acini in rat and guinea pig and both are responsible for mediating the action of VIP. These results can effect future studies of activation of VIP receptors on pancreatic function in a number of ways. In future studies of the effects of any VIP/pituitary adenylate cyclase-activating polypeptide analogs on pancreatic function, it will be important to consider their abilities to interact with both the VIP 1 -R and the VIP 2 -R and activate these receptors. Differing results could be obtained from VIP itself, which is a highaffinity agonist for both VIP-R subtypes. Furthermore, in future studies of the action of VIP on pancreatic acini, it will be important to consider the participation of the different VIP receptor subtypes, a factor not included in older studies. The availability of selective agonists for each receptor subtype should make this analysis easier, and these should be valuable tools in establishing a better understanding of the physiological roles of both VIP receptor subtypes in pancreatic acini.
